About Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Effect of ADHD Drugs on the Brain - Study Finds

by Medindia Content Team on June 26, 2006 at 4:03 PM
Font : A-A+

Effect of ADHD Drugs on the Brain - Study Finds

Investigating on the target areas, where ADHD drugs act, researchers have concluded that it primarily targets the prefrontal cortex (PFC) region of the brain rather than on accumbens and medial septum regions.

Researchers at the University of Wisconsin-Madison found how the drug Ritalin used in treating the symptoms of attention deficit hyperactivity disorder (ADHD), works in the brain.

Advertisement

But new work at the University of Wisconsin-Madison is now starting to clear up some of the mystery. Writing in the journal Biological Psychiatry, UW-Madison researchers report that ADHD drugs primarily target the prefrontal cortex (PFC), a region of the brain that is associated with attention, decision-making and an individual's expression of personality.

The finding could prove invaluable in the search for new ADHD treatments, and comes amidst deep public concern over the widespread abuse of existing ADHD medicines.
Advertisement

'There's been a lot of concern over giving a potentially addictive drug to a child [with ADHD],' says lead author Craig Berridge, a UW-Madison professor of psychology. 'But in order to come up with a better drug we must first know what the existing drugs do.'

A behavioral disorder that afflicts both children and adults, ADHD is marked by hyperactivity, impulsivity and an inability to concentrate. The National Institute of Mental Health estimates that 2 million children in the U.S. suffer from the condition, with between 30 to 70 percent of them continuing to exhibit symptoms in their adult years.

Despite public anxiety over the treatment of a behavioral condition with pharmacological drugs, doctors have continued to prescribe meds like Adderall, Ritalin and Dexedrine because - quite simply - they work better than anything else.

ADHD drugs fall into a class of medications known as stimulants. ADHD stimulants boost levels of two neurotransmitters, or chemical messengers in the brain, known as dopamine and norepinephrine. Dopamine is thought to play a role in memory formation and the onset of addictive behaviors, while norepinephrine has been linked with arousal and attentiveness.

Berridge notes that scientists have learned little about how ADHD drugs work because past studies have primarily examined the effects of the medicines at high doses. High-dose stimulants can cause dramatic spikes in neurotransmitter levels in the brain, which can in turn impair attention and heighten the risk of developing addiction.

'It is surprising that no one was looking at low-dose [ADHD] drugs because we know that the drugs are most effective only at low doses,' says Berridge. 'So we asked the natural question: what are these drugs doing at clinically relevant doses?'

To answer that question, Berridge and his team monitored neurotransmitter levels in three different brain regions thought to be targeted by ADHD drugs: the PFC and two smaller brain areas known as the accumbens which has been linked with processing 'rewards,' and the medial septum, which has been implicated in arousal and movement.

Working with rats, the researchers conducted laboratory and behavioral tests to ensure that animal drug doses were functionally equivalent to doses prescribed in humans. Then, using a type of brain probe - a process known as microdialysis - the UW-Madison team measured concentrations of dopamine and norepinephrine in the three different brain areas, both in the presence and absence of low-dose ADHD stimulants.

Under the influence of ADHD drugs, dopamine and norepinephrine levels increased in the rats' PFC. Levels in the accumbens and medial septum, however, remained much the same, the scientists found.

'Our work provides pretty important information on the importance of targeting the PFC when treating ADHD,' says Berridge, 'In particular it tells us that if we want to produce new ADHD drugs, we need to target [neurotransmitter] transmission in the PFC.'

In the future, Berridge and his colleagues plan to look deeper within the PFC to gain more detailed insights into how ADHD meds act on nerves to enhance cognitive ability.

Other researchers who contributed to the study include UW-Madison co-authors David Devilbiss, Matthew Andrzejewski, Ann Kelley, Brooke Schmeichel, Christina Hamilton and Robert Spencer, and Yale Medical School researcher Amy Arnsten.

(Source: Eurekalert)
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Monkeypox Outbreak: What it is, How Does it Spread & the Prevention
Seasonal Allergy Medications
How to Choose the Best Eczema-Friendly Moisturizer for Children?
View all
Recommended Reading
News Archive
Date
Category
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Drug Toxicity Dyslexia Attention Deficit Hyperactivity Disorder (ADHD) Parkinsons Disease Parkinsons Disease Surgical Treatment Signature Drug Toxicity Bullying at School - Tips For Schools Brain ADHD Dyscalculia / Learning Disabilities 

Most Popular on Medindia

Loram (2 mg) (Lorazepam) The Essence of Yoga Selfie Addiction Calculator Blood - Sugar Chart Daily Calorie Requirements Find a Doctor Drug - Food Interactions Calculate Ideal Weight for Infants Blood Pressure Calculator Accident and Trauma Care

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2022

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use
open close
CONSULT A DOCTOR